Additional studies that use other therapeutics to inhibit CCL2 either alone or indirectly by targeting the CCR2 to diminish the ratio, as with the alternative medicinal inhibitory organometallic compound PG, might be needed to confirm whether CCL2 is an important contributor to disease indication or outcome in pancreatic cancer. The gene discussed is CCR2; the disease is familial pancreatic carcinoma.